Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia

Cancer

Volumn 120, Issue 13, 2014, Pages 1985-1992

  Inaba, Hiroto ^a,b   Gaur, Aditya H ^a,b   Cao, Xueyuan ^a   Flynn, Patricia M ^a,b   Pounds, Stanley B ^a   Avutu, Viswatej ^a   Marszal, Lindsay N ^a   Howard, Scott C ^a,b   Pui, Ching Hon ^a,b   Ribeiro, Raul C ^a,b   Hayden, Randall T ^a   Rubnitz, Jeffrey E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; antibiotics; children; infection; prophylaxis

Indexed keywords

CASPOFUNGIN; CEFEPIME; CEFPODOXIME; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CYTARABINE; DAUNORUBICIN; ECHINOCANDIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; MICAFUNGIN; VANCOMYCIN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CHILD; CLINICAL PROTOCOL; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HUMAN; INFANT; INFECTION PREVENTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RETROSPECTIVE STUDY; SCHOOL CHILD; YOUNG ADULT;

ACUTE MYELOID LEUKEMIA; ANTIBIOTICS; CHILDREN; INFECTION; PROPHYLAXIS;

ADMINISTRATION, ORAL; ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BACTERIAL INFECTIONS; CANDIDIASIS; CEPHALOSPORINS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CONSOLIDATION CHEMOTHERAPY; DRUG THERAPY, COMBINATION; FEASIBILITY STUDIES; FEMALE; HUMANS; INCIDENCE; INDUCTION CHEMOTHERAPY; INFANT; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM STAGING; NOSE; OUTPATIENTS; RECTUM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN; YOUNG ADULT;

EID: 84902550473     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28688     Document Type: Article

References (28)

1. Rubnitz JE, Inaba H,. Childhood acute myeloid leukaemia. Br J Haematol. 2012; 159: 259-276.
2. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012; 120: 3187-3205.
3. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J,. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007; 110: 3532-3539.
4. Lehrnbecher T, Varwig D, Kaiser J, Reinhardt D, Klingebiel T, Creutzig U,. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004; 18: 72-77.
5. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T,. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004; 22: 4384-4393.
6. Gamis AS, Howells WB, DeSwarte-Wallace J, Feusner JH, Buckley JD, Woods WG,. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891. J Clin Oncol. 2000; 18: 1845-1855.
7. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008; 113: 376-382.
8. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005; 353: 977-987.
9. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005; 353: 988-998.
10. Gafter-Gvili A, Fraser A, Paul M, Leibovici L,. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005; 142: 979-995.
11. Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS,. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group. Blood. 2013; 121: 3573-3577.
12. Sung L, Aplenc R, Zaoutis T, Groll AH, Gibson B, Lehrnbecher T,. Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions. Pediatr Blood Cancer. 2008; 51: 458-460.
13. Alexander S, Nieder M, Zerr DM, Fisher BT, Dvorak CC, Sung L,. Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn? Pediatr Blood Cancer. 2012; 59: 16-20.
14. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11: 543-552.
15. O'Hear C, Inaba H, Pounds S, et al. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer. 2013; 119: 4036-4043.
16. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. Accessed March 18, 2014.
17. Gaur A, Giannini MA, Flynn PM, et al. Optimizing blood culture practices in pediatric immunocompromised patients: evaluation of media types and blood culture volume. Pediatr Infect Dis J. 2003; 22: 545-552.
18. Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network Protocol. cdc.gov/nhsn/pdfs/pscmanual/4psc-clabscurrent.pdf. Accessed March 18, 2014.
19. Sung L, Gamis A, Alonzo TA, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009; 115: 1100-1108.
20. Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol. 2009; 147: 125-128.
21. Lehrnbecher T, Aplenc R, Rivas Pereira F, et al, SIOP Supportive Care Working Group,. Variations in non-pharmacological anti-infective measures in childhood leukemia-results of an international survey. Haematologica. 2012; 97: 1548-1552.
22. Bagga B, Shenep JL,. Management of infections caused by vancomycin-resistant gram-positive bacteria. Pediatr Infect Dis J. 2010; 29: 662-664.
23. Pournaras S, Iosifidis E, Roilides E,. Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol. 2009; 46: 198-211.
24. Kosack A, Riedel E, Kiehn TE, Small TN, Wexler LH, Dunkel IJ,. Vancomycin-resistant enterococcus in pediatric oncology patients: an analysis of potential consequences of colonization and infection. Pediatr Blood Cancer. 2009; 52: 300-302.
25. Haeusler GM, Mechinaud F, Daley A, et al. Antibiotic resistant gram-negative bacteremia in pediatric oncology patients-risk factors and outcome. Pediatr Infect Dis J. 2013; 32: 723-726.
26. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44: 159-177.
27. Rubnitz JE, Crews KR, Pounds S, et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia. 2009; 23: 1410-1416.
28. Maron GM, Hayden RT, Rodriguez A, et al. Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections. Pediatr Infect Dis J. 2013; 32: e451-e455.